HAS Healthcare Advanced Synthesis Celebrates 40 Years with the Inauguration of a New Cutting-Edge Quality Control Laboratory Center at its Manufacturing Plant in Biasca, Switzerland

Significant new investments for HAS Healthcare Advanced Synthesis driven by expanding demand for the development and analyses of traditional and anticancer molecules, and to support the future growth of the plant.

Biasca, Switzerland, April 17, 2024

In a momentous stride toward the future, HAS Healthcare Advanced Synthesis SA (“HAS”), a full-service contract development and manufacturing organization (CDMO) delivering high-quality, exclusive, personalized solutions to our healthcare clients, proudly announces the inauguration of the new Quality Control Laboratory Center at our manufacturing plant in Biasca, Switzerland. This significant investment coincides with our celebration of our 40th anniversary, marking a remarkable milestone in our company’s history.

Driven by the ever-expanding demand for groundbreaking research and development, our new Quality Control Laboratory Center, equipped with cutting-edge technology, is set-up to rigorously test and ensure the safety and efficacy of high quality Active Pharmaceutical Ingredients (APIs), as well as to handle, sample, and analyze Highly Potent Active Pharmaceutical Ingredients (HPAPIs), in addition to cytotoxic products.

Key Highlights:

  1. 40 Years of Excellence: Since our inception four decades ago, HAS has been at the forefront of scientific progress and innovation. Our commitment to excellence remains unwavering, and this inauguration underscores our dedication to pushing boundaries.
  2. Meeting Growing Demand: The surge in business volume and increased activities over recent years necessitated the creation of this cutting-edge Quality Control Laboratory Center, which will help our skilled and talented team develop high-quality, exclusive, personalized solutions to our healthcare clients.
  3. Traditional and Anticancer Molecules: Our laboratory center will focus on the development, analyses, and optimization of both traditional and anticancer compounds. We aim to make a lasting impact on global health and help patients worldwide enjoy a better quality of life.
  4. Future Growth: This investment is not just about the present; it is about securing our future. The new center will fuel our growth path, enabling us to meet the evolving needs of patients and healthcare providers worldwide.
  5. Innovation and Sustainability: Innovation and sustainability lie at the core of our values. We conscientiously manage our assets, striving to minimize our environmental impact while enhancing our contribution to the local community. As we embrace new technologies, we remain steadfast in our commitment to sustainability. Our Quality Control Laboratory Center is designed with eco-friendly practices, ensuring that progress does not come at the expense of our planet.

Dr. Waldo Mossi, Chief Executive Officer at HAS, expressed his enthusiasm: “Our new Quality Control Laboratory Center represents the culmination of decades of hard work, collaboration, and unwavering passion. It symbolizes our dedication to remaining at the cutting edge of technology while maintaining a strong commitment to sustainability. The Center will play a pivotal role in advancing science, better serving our clients and providing patients with the possibility of enjoying an enhanced quality of life”.

The inauguration ceremony, attended by esteemed guests, local authorities, and our dedicated team, was a testament to our shared vision. Our new Quality Control Laboratory Center will play a pivotal role in advancing scientific discovery and enhancing patient outcomes as we step into our fourth decade.


About HAS

HAS Healthcare Advanced Synthesis is a CDMO that offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds.

The production facility is located in Biasca, Switzerland, and was founded in 1984. The site is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.

For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin

Contact Press Office

HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]